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CATEGORIZATION OF RISK OF PROSTATE 
CANCER: PILOT TEST OF CLINICAL OUTCOMES 
AND RISK PERCEPTIONS
Bruner DW, Parlanti AA, Ross E, Raysor S, Mazzoni SE, 
Hanks GE
Fox Chase Cancer Center, Philadelphia, PA, USA
OBJECTIVES: To define clinically useful categories for
prostate cancer (PC) risk and associated outcomes.
Translating relative risk (RR) and cumulative risk (CR)
into risk categories is important if studies of PC epidemi-
ology and genetic predisposition are to have clinical util-
ity for education, counseling and decision-making. Indi-
vidual risk perceptions compared to clinical risk are
important for the study of behavioral outcomes. METH-
ODS: Risk categories were determined by an extensive
review of the literature. Using RR and CR for specific
risk factors, 4 categories were defined from low to very
high. The categories were then used to assess PC out-
comes in men at increased risk for PC (defined by race
and family history). Risk perceptions were assessed by
asking men to rate their chance of getting PC on a scale
from 0 to 100%. RESULTS: 264 men participated in this
study. Mean age was 47.7 years, and 52% were African
American, 48% were Caucasian. By nature of study eligi-
bility, only 3(1%) men were in the low risk category. Ac-
cording to study criteria, 54(20%) were in the moderate
risk, 129(49%) in the high risk, and 62(24%) in the very
high risk categories, 16(6%) were unknown. PC was di-
agnosed in 0 of the low and unknown, 7% of the moder-
ate, 5% of the high and 10% of the very high-risk
groups. Of the 62 men who answered the risk perception
item, there was no correlation between risk category and
risk perceptions. CONCLUSIONS: Lacking a Gail-like
model for PC risk, the search continues for quantifiable
risk categories with clinical utility. The extreme catego-
ries proposed in this pilot study show a trend toward
clinically meaningful categorization of PC risk. A meta-
analysis of RR and CR is underway to refine the catego-
ries. Risk categories and risk perceptions were not associ-
ated, as has been shown in breast cancer.
PCN2
WHICH VARIABLES DO METASTATIC BREAST 
CANCER PATIENTS AND ONCOLOGY NURSES 
ANCHOR ON WHEN USING THE EUROQOL 
DESCRIPTIVE SYSTEM IN MEASURING 
UTILITIES WITH THE STANDARD
GAMBLE TECHNIQUE?
Hauser R1,2, Koeller J1
1University of Texas at Austin, Austin, TX, USA; 2Abt 
Associates Clinical Trials, Cambridge, MA, USA
OBJECTIVE: To determine which of seven EuroQoL de-
scriptives used in collecting utility scores were the an-
chors for metastatic breast cancer patients (pts) and on-
cology nurses (nur). METHODS: Eight states of health
describing metastatic breast cancer were presented to 45
pts and 56 nur. Each health state had seven bullet points
describing varying degrees of severity in the following
categories: Mobility, Activities of Daily Living (ADL),
Hand/finger use (NOT EuroQoL), Usual Activity, Anxi-
ety/Depression, Ability to think (NOT EuroQoL), and
Pain/Discomfort. After the utility scores were obtained,
subjects were asked which of the seven variables were
most important and second most important to them.
RESULTS:
CONCLUSIONS: It appears that both pts and nur an-
chored mainly on the Self-Care variable. Combining the
most important with the next most important variable
demonstrates that the Anxiety/Depression variable was
also an important anchoring variable for both groups. Pts
appear to anchor more on Usual Activity than nur. Nur
appear to anchor more on Pain/Discomfort than pts. The
results also suggest that the Hand and Finger use variable
(NOT a EuroQoL variable) may not be necessary and
may actually overburden subjects. Overall, these finding
may help explain why metastatic breast cancer patients
differ from oncology nurses on utility scores.
PCN3
PREDICTORS OF CHEMOTHERAPY-RELATED 
NEUTROPENIA: A REVIEW OF THE
CLINICAL LITERATURE
Palmer C1, Brown R1, Wilson-Royalty M2, Lawless G2
1MEDTAP International Inc, Bethesda, MD, USA; 2Amgen, Inc, 
Thousand Oaks, CA, USA
OBJECTIVES: A literature review was conducted to
identify risk factors and predictors of chemotherapy-
related grade 3–4 and/or febrile neutropenia to assist
PATIENTS, N45
Most
Important
Variable,
N (%)
Next Most
Important
Variable,
N (%)
Row
Total,
N (%)
Mobility 11 (24.4) 3 (6.7) 14 (31.1)
ADL or Self Care 14 (31.1) 10 (22.2) 24 (53.3)
Hand or finger use 0 (0) 0 (0) 0 (0)
Usual Activity 3 (6.7) 7 (15.6) 10 (22.2)
Anxiety/Depression 9 (20.0) 11 (24.4) 20 (44.4)
Ability to Think 5 (11.1) 10 (22.2) 15 (33.3)
Pain/Discomfort 3 (6.7) 4 (8.9) 7 (15.6)
Column Total 45 (100%) 45 (100%)
NURSES, N56
Mobility 9 (16.1) 7 (12.5) 16 (28.6)
ADL or Self Care 18 (32.1) 14 (25.0) 32 (57.1)
Hand or finger use 0 (0) 0 (0) 0 (0)
Usual Activity 1 (1.8) 3 (5.4) 4 (7.2)
Anxiety/Depression 14 (25.0) 15 (26.8) 29 (51.8)
Ability to Think 4 (7.1) 9 (16.1) 13 (23.2)
Pain/Discomfort 10 (17.9) 8 (14.3) 18 (32.2)
Column Total 56 (100%) 56 (100.1% rounded)
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with assessing who might benefit from treatments such as
prophylactic G-CSF. METHODS: The literature review
included publications from 1990–2000 of adults with
any tumor type; 121 articles were identified that refer-
enced risk factors or predictors for severe/febrile neutro-
penia. Study design, patient characteristics, chemother-
apy treatment, and incidences of neutropenia were
recorded. RESULTS: Twenty-one relevant publications,
including prospective, retrospective, and modeling stud-
ies, were further analyzed. These articles yielded 27 po-
tential risk factors/predictors in 3 categories: patient (n 
14), treatment-related (n  8), and disease-related (n 
5) characteristics. Although most of the 27 potential risk
factors/predictors were not validated to identify patients
at higher risk for severe/febrile neutropenia, the review
suggests that several simple-to-use and commonly avail-
able risk factors may be reliable predictors of neutrope-
nia. These included low hemoglobin and neutrophil
counts in cycle one; depth of the neutrophil nadir; low
lymphocyte, monocyte and platelet levels; and a precipi-
tous, early drop in blood cell counts. Several other risk
factors, such as serum albumin 3.5g/dL on day 1, se-
rum LDH 1	 normal alone or combined with bone
marrow involvement, and high dose chemotherapy, also
warrant further investigation. CONCLUSIONS: Few
studies have explicitly explored risk factors associated
with the occurrence of Grade 3–4 neutropenia. However,
this literature review identified several common charac-
teristics that may be measured with early and frequent
CBC monitoring and may reasonably predict predisposi-
tion of patients to severe/febrile neutropenia.
PCN4
COMPARING MEAN VERSUS MEDIAN SURVIVAL 
AS A PRELUDE TO COST-EFFECTIVENESS
(C/E) ANALYSES
Gagnon DD1, Martin SC1, van Hout B2
1The R.W. Johnson Pharmaceutical Research Institute, Raritan, 
NJ, USA; 2Utrecht University, Utrecht, Netherlands
BACKGROUND: In a multinational trial designed to
determine the efficacy of epoetin alfa in chemotherapy-
induced anemia, patients receiving non-platinum chemo-
therapy having a hemoglobin 10.5 g/dL or less, or a decline
in hemoglobin of 1.5 g/dL or greater were randomized
(2:1) to epoetin alfa or placebo. A total of 375 patients
(251 epoetin alfa, 124 placebo) were assessed for survival
status twelve months after completing the protocol, but
prior to unblinding. A log-rank test showed a trend in
survival favoring epoetin alfa (median of 17 vs. 11
months, p  0.128). OBJECTIVES: The primary efficacy
endpoint for many cancer clinical trials is median sur-
vival. In preparing for an economic analysis, however, we
analyzed mean survival, the appropriate survival end-
point for a C/E analysis. METHODS: Sampling with re-
placement, we conducted a post hoc analysis that exam-
ined the difference in mean survival by drawing 10,000
samples in a bootstrapping simulation. Within each sam-
ple the survival curves were truncated to maintain identi-
cal follow-up periods between treatment groups. The dif-
ference in mean survival was computed for each sample.
The probability of superior efficacy was obtained by sort-
ing the results from the samples. RESULTS: The average
mean survival difference, across the 10,000 samples,
showed a 0.212-year survival benefit for epoetin alfa.
The probability that the difference in mean survival fa-
vors epoetin alfa was 0.965. CONCLUSIONS: Compar-
ing differences in median and mean survival may lead to
different conclusions about the value of a therapy. Given
that mean survival is the appropriate effectiveness end-
point for survival-based C/E analyses, a non-significant
difference in median survival does not preclude full C/E
analyses. Specifically, the mean survival results from this
trial warrant a full C/E analysis of epoetin alfa in treating
anemia for patients receiving non-platinum chemotherapy.
PCN5
DOCETAXEL/DOXORRUBICIN (DD) AS FIRST 
LINE CHEMOTHERAPY: QUALITY OF LIFE (QOL) 
IN PATIENTS (PTS) WITH METASTATIC BREAST 
CANCER (MBC)
Bonicatto SC
FUNDONAR Foundation, La Plata, Argentina
OBJECTIVE: In spite of initial treatment of MBC with DD
showed high level of efficacy expressed as improved dis-
ease-free interval, time to relapse and overall response, it re-
mains as a palliative one. Because of there is some evidence
that QOL is improved with this treatment, we designed the
study to investigate the impact and changes on QOL in pa-
tients (pts) with MBC treated with DD, and its relationship
with clinical parameter of response. Material and METH-
ODS: Between July 1999 and July 2000, we treated 42
MBC pts with doxorrubicin 50mg/m2 and docetaxel 75
mg/m2, i.v., day 1. Inclusion criteria: female between 18–
75 years old, ECOG PS 0-2, and stage IV of MBC histolog-
ically confirmed. QOL was assessed at baseline and prior to
the first, third and fifth cycle of chemotherapy with the
EORTC QLQ-C30 version 2.0, an integrated measurement
system to evaluate QOL of cancer pts. RESULTS: To date,
33 pts (median age  51.7; range 40–67) with available
data, have completed 5 cycles of chemotherapy. Repeated
measures analysis of variance (MANOVA) showed time ef-
fects statistically significant (p  0.5) for Emotional Func-
tioning (EF; p  .001), and Cognitive Functioning (EF; p 
.001) scales, and pain (p  .000), insomnia (p  .05) and
constipation (p  .02) symptom scales. When baseline
QOL was compared with that after 5 cycles (paired t-test),
it was observed significant improved in EF (p  .003), pain
(p  .005) and Insomnia (p  .04). We grouped pts with
CR and PR (n  14) for comparing with SD pts (n  19)
and we observed significantly improve in the first group af-
ter the fifth cycle, in physical functioning (p  .05) and so-
cial functioning (p  .005). CONCLUSION: These prelim-
inary data suggest that pts with MBC undergoing DD
chemotherapy experience improvement in several QOL pa-
